The long-term oxygen treatment trial for chronic obstructive pulmonary disease

Rationale, design, and lessons learned

for the LOTT Research Group

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The Long-Term Oxygen Treatment Trial demonstrated that long-term supplemental oxygen did not reduce time to hospital admission or death for patients who have stable chronic obstructive pulmonary disease and resting and/or exercise-induced moderate oxyhemoglobin desaturation, nor did it provide benefit for any other outcome measured in the trial. Nine months after initiation of patient screening, after randomization of 34 patients to treatment, a trial design amendment broadened the eligible population, expanded the primary outcome, and reduced the goal sample size. Within a few years, the protocol underwent minor modifications, and a second trial design amendment lowered the required sample size because of lower than expected treatment group crossover rates. After 5.5 years of recruitment, the trial met its amended sample size goal, and 1 year later, it achieved its follow-up goal. The process of publishing the trial results brought renewed scrutiny of the study design and the amendments. This article expands on the previously published design and methods information, provides the rationale for the amendments, and gives insight into the investigators' decisions about trial conduct. The story of the Long-Term Oxygen Treatment Trial may assist investigators in future trials, especially those that seek to assess the efficacy and safety of long-term oxygen therapy.

Original languageEnglish (US)
Pages (from-to)89-101
Number of pages13
JournalAnnals of the American Thoracic Society
Volume15
Issue number1
DOIs
StatePublished - Jan 1 2018
Externally publishedYes

Fingerprint

Chronic Obstructive Pulmonary Disease
Oxygen
Sample Size
Research Personnel
Therapeutics
Oxyhemoglobins
Random Allocation
Exercise
Safety
Population

Keywords

  • Chronic obstructive pulmonary disease
  • Hypoxemia
  • Oxygen
  • Randomized controlled trial
  • Survival

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

The long-term oxygen treatment trial for chronic obstructive pulmonary disease : Rationale, design, and lessons learned. / for the LOTT Research Group.

In: Annals of the American Thoracic Society, Vol. 15, No. 1, 01.01.2018, p. 89-101.

Research output: Contribution to journalArticle

@article{273c038ad7694a3b90f3b9724380f9dc,
title = "The long-term oxygen treatment trial for chronic obstructive pulmonary disease: Rationale, design, and lessons learned",
abstract = "The Long-Term Oxygen Treatment Trial demonstrated that long-term supplemental oxygen did not reduce time to hospital admission or death for patients who have stable chronic obstructive pulmonary disease and resting and/or exercise-induced moderate oxyhemoglobin desaturation, nor did it provide benefit for any other outcome measured in the trial. Nine months after initiation of patient screening, after randomization of 34 patients to treatment, a trial design amendment broadened the eligible population, expanded the primary outcome, and reduced the goal sample size. Within a few years, the protocol underwent minor modifications, and a second trial design amendment lowered the required sample size because of lower than expected treatment group crossover rates. After 5.5 years of recruitment, the trial met its amended sample size goal, and 1 year later, it achieved its follow-up goal. The process of publishing the trial results brought renewed scrutiny of the study design and the amendments. This article expands on the previously published design and methods information, provides the rationale for the amendments, and gives insight into the investigators' decisions about trial conduct. The story of the Long-Term Oxygen Treatment Trial may assist investigators in future trials, especially those that seek to assess the efficacy and safety of long-term oxygen therapy.",
keywords = "Chronic obstructive pulmonary disease, Hypoxemia, Oxygen, Randomized controlled trial, Survival",
author = "{for the LOTT Research Group} and Yusen, {Roger D.} and Criner, {Gerard J.} and Sternberg, {Alice L.} and Au, {David H.} and Fuhlbrigge, {Anne L.} and Albert, {Richard K.} and Richard Casaburi and Stoller, {James K.} and Harrington, {Kathleen F.} and Cooper, {J. Allen D.} and Philip Diaz and Steven Gay and Richard Kanner and Neil MacIntyre and Martinez, {Fernando J.} and Steven Piantadosi and Frank Sciurba and David Shade and Thomas Stibolt and James Tonascia and Robert Wise and Bailey, {William C.} and Ernestina Sampong and Karin Sloan and Ashley Wagner and Susan Anderson and Marilyn Moy and Osarenoma Okunbor and Scott Marlow and Yvonne Meli and Richard Rice and Aboussouan, {Loutfi S.} and Robert Castele and Joseph Parambil and Sumita Khatri and Aman Pande and Joe Zein and Thomas Olbrych and Stephan Alkins and Christine Jocko and Franck Rahaghi and Jean Barton and Jennifer Underwood and Barry Make and John Davies and Richard Mularski and Allison Naleway and Sarah Vertrees and Janos Porszasz and Anzueto, {Antonio R}",
year = "2018",
month = "1",
day = "1",
doi = "10.1513/AnnalsATS.201705-374SD",
language = "English (US)",
volume = "15",
pages = "89--101",
journal = "Annals of the American Thoracic Society",
issn = "2325-6621",
publisher = "American Thoracic Society",
number = "1",

}

TY - JOUR

T1 - The long-term oxygen treatment trial for chronic obstructive pulmonary disease

T2 - Rationale, design, and lessons learned

AU - for the LOTT Research Group

AU - Yusen, Roger D.

AU - Criner, Gerard J.

AU - Sternberg, Alice L.

AU - Au, David H.

AU - Fuhlbrigge, Anne L.

AU - Albert, Richard K.

AU - Casaburi, Richard

AU - Stoller, James K.

AU - Harrington, Kathleen F.

AU - Cooper, J. Allen D.

AU - Diaz, Philip

AU - Gay, Steven

AU - Kanner, Richard

AU - MacIntyre, Neil

AU - Martinez, Fernando J.

AU - Piantadosi, Steven

AU - Sciurba, Frank

AU - Shade, David

AU - Stibolt, Thomas

AU - Tonascia, James

AU - Wise, Robert

AU - Bailey, William C.

AU - Sampong, Ernestina

AU - Sloan, Karin

AU - Wagner, Ashley

AU - Anderson, Susan

AU - Moy, Marilyn

AU - Okunbor, Osarenoma

AU - Marlow, Scott

AU - Meli, Yvonne

AU - Rice, Richard

AU - Aboussouan, Loutfi S.

AU - Castele, Robert

AU - Parambil, Joseph

AU - Khatri, Sumita

AU - Pande, Aman

AU - Zein, Joe

AU - Olbrych, Thomas

AU - Alkins, Stephan

AU - Jocko, Christine

AU - Rahaghi, Franck

AU - Barton, Jean

AU - Underwood, Jennifer

AU - Make, Barry

AU - Davies, John

AU - Mularski, Richard

AU - Naleway, Allison

AU - Vertrees, Sarah

AU - Porszasz, Janos

AU - Anzueto, Antonio R

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The Long-Term Oxygen Treatment Trial demonstrated that long-term supplemental oxygen did not reduce time to hospital admission or death for patients who have stable chronic obstructive pulmonary disease and resting and/or exercise-induced moderate oxyhemoglobin desaturation, nor did it provide benefit for any other outcome measured in the trial. Nine months after initiation of patient screening, after randomization of 34 patients to treatment, a trial design amendment broadened the eligible population, expanded the primary outcome, and reduced the goal sample size. Within a few years, the protocol underwent minor modifications, and a second trial design amendment lowered the required sample size because of lower than expected treatment group crossover rates. After 5.5 years of recruitment, the trial met its amended sample size goal, and 1 year later, it achieved its follow-up goal. The process of publishing the trial results brought renewed scrutiny of the study design and the amendments. This article expands on the previously published design and methods information, provides the rationale for the amendments, and gives insight into the investigators' decisions about trial conduct. The story of the Long-Term Oxygen Treatment Trial may assist investigators in future trials, especially those that seek to assess the efficacy and safety of long-term oxygen therapy.

AB - The Long-Term Oxygen Treatment Trial demonstrated that long-term supplemental oxygen did not reduce time to hospital admission or death for patients who have stable chronic obstructive pulmonary disease and resting and/or exercise-induced moderate oxyhemoglobin desaturation, nor did it provide benefit for any other outcome measured in the trial. Nine months after initiation of patient screening, after randomization of 34 patients to treatment, a trial design amendment broadened the eligible population, expanded the primary outcome, and reduced the goal sample size. Within a few years, the protocol underwent minor modifications, and a second trial design amendment lowered the required sample size because of lower than expected treatment group crossover rates. After 5.5 years of recruitment, the trial met its amended sample size goal, and 1 year later, it achieved its follow-up goal. The process of publishing the trial results brought renewed scrutiny of the study design and the amendments. This article expands on the previously published design and methods information, provides the rationale for the amendments, and gives insight into the investigators' decisions about trial conduct. The story of the Long-Term Oxygen Treatment Trial may assist investigators in future trials, especially those that seek to assess the efficacy and safety of long-term oxygen therapy.

KW - Chronic obstructive pulmonary disease

KW - Hypoxemia

KW - Oxygen

KW - Randomized controlled trial

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85039777036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039777036&partnerID=8YFLogxK

U2 - 10.1513/AnnalsATS.201705-374SD

DO - 10.1513/AnnalsATS.201705-374SD

M3 - Article

VL - 15

SP - 89

EP - 101

JO - Annals of the American Thoracic Society

JF - Annals of the American Thoracic Society

SN - 2325-6621

IS - 1

ER -